Abstract PROteolysis TArgeting Chimeras (PROTACs) technology is a new protein-
degradation strategy that has emerged in recent years. It uses bifunctional small molecules …

Targeted protein degradation (TPD) is emerging as a strategy to overcome the limitations of
traditional small-molecule inhibitors. Proteolysis-targeting chimera (PROTAC) technology …

Triple-negative breast cancer (TNBC) is highly aggressive with a poor clinical prognosis and
no targeted therapy. The c-Myc protein is a master transcription factor and a potential …

Proteolysis targeting chimera (PROTAC)-mediated protein degradation has prompted a
radical rethink and is at a crucial stage in driving a drug discovery transition. To fully harness …

Introduction Target protein degradation (TPD) provides a novel therapeutic modality, other
than inhibition, through the direct depletion of target proteins. Two primary human protein …

The success of inhibitor-based therapeutics is largely constrained by the acquisition of
therapeutic resistance, which is partially driven by the undruggable proteome. The …

The utilization of proximity-mediated effects to perturb pathogenic proteins of interest (POIs)
has emerged as a powerful strategic alternative to conventional drug design approaches …

Combination of different molecular target inhibitors is an available method to improve the
therapeutic effect on tumors. Herein, to achieve both tumor cell targeting and ALK …

Proteolysis-targeting chimeras (PROTACs) are heterobifunctional molecules consisting of
two ligands joined by a linker, enabling them to simultaneously bind with an E3 ligase and a …

Proteolysis-targeting chimera (PROTAC) technology is a disruptive innovation in the drug
development community, and over 20 PROTAC molecules are currently under clinical …